GlassScriptPhysician profile
Patrick Ryan Honeycutt
NPI 1356703185
$10,696.72
in general payments reported to CMS, 2019-2025
33 companies · $3,217 in 2025
The $3,217 reported for 2025 was more than what 90% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $789 · 2021: $453 · 2022: $1,312 · 2023: $1,739 · 2024: $2,803 · 2025: $3,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,531 · Food and Beverage: $2,480 · Long Term Medical Supply Or Device Loan: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,531.49 |
| Food and Beverage | $2,479.65 |
| Long Term Medical Supply Or Device Loan | $1,747.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,715.96 | 2019-2025 | Ortholoc 2 Lapifuse, Prostep Mica, Prostep |
| Integra Lifesciences Corporation | $2,625.19 | 2022-2025 | Integra, Amnioexcel Plus, Primatrix |
| Smith+Nephew, INC. | $1,075.90 | 2019-2025 | Grafix Pl, Bone Anchors With Arthroscopic Delivery System, Grafix |
| Treace Medical Concepts, INC. | $1,032.17 | 2025 | |
| Musculoskeletal Transplant Foundation INC. | $462.99 | 2020-2021 | |
| Aroa Biosurgery Incorporated | $338.30 | 2022 | |
| In2bones USA, LLC | $148.50 | 2022 | |
| Organogenesis INC. | $138.60 | 2022-2023 | Puraply |
| Horizon Therapeutics Plc | $136.43 | 2019-2023 | Krystexxa |
| Abbvie INC. | $92.07 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $87.79 | 2020-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $85.13 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $78.77 | 2020-2023 | Dermaspan Tissue Expander |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $65.22 | 2022 | |
| Mvp Orthopedics INC | $57.63 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $52.84 | 2020-2023 | 3m Cavilon, Activ.A.C. |
| Flower Orthopedics Coporation | $45.30 | 2021 | |
| Kerecis Limited | $43.01 | 2019-2020 | |
| Bioventus LLC | $40.81 | 2019-2022 | |
| Polynovo North America LLC | $38.43 | 2025 | Novosorb Btm |
| Embody, INC. | $37.28 | 2021 | |
| Merck Sharp & Dohme LLC | $35.70 | 2019 | |
| Reprise Biomedical, INC. | $34.51 | 2024 | Miro3d |
| Next Science LLC | $33.30 | 2023 | Xperience, Blastx, Surgx |
| Zyla Life Sciences, INC. | $30.47 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $24.39 | 2019 | |
| Medtronic, INC. | $24.16 | 2023 | Intellis Adaptivestim |
| Trice Medical, INC. | $24.05 | 2025 | |
| Lifenet Health | $23.03 | 2023 | |
| Cardiovascular Systems INC. | $22.92 | 2019 | |
| Electronic Waveform Lab, INC. | $20.31 | 2019 | |
| Depuy Synthes Sales INC. | $13.02 | 2022 | |
| Sebela Pharmaceuticals INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Honeycutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.